摘要
Abstract
Objective:To investigate the clinical efficacy of camrelizumab combined with paclitaxel+cisplatin(TP)chemotherapy in the treatment of oesophageal cancer.Methods:A total of 72 patients with oesophageal cancer treated in a hospital from June 2019 to June 2022 were selected and assigned to the control group and the observation group by random number table method,with 36 patients in each group.The control group was treated with TP chemotherapy,and the observation group was treated with camrelizumab for injection in addition to the treatment given in the control group.Both groups were treated for 4 courses.The levels of tumor markers[squamous cell carcinoma antigen(SCCA),carcinoembryonic antigen(CEA)],T lymphocyte subsets(CD4+,CD8+,CD4+/CD8+),quality of life[Karnofsky performance score(KPS)],clinical efficacy,adverse reactions and 12-month survival after treatment were compared between the two groups.Results:After treatment,the levels of serum SCCA and CEA were decreased in both groups(P<0.05),with the observation group showing lower levels than the control group(P<0.05).CD8+in the observation group was lower than that in the control group(P<0.05),while CD4+and CD4+/CD8+were higher than those in the control group(P<0.05).The KPS score was increased in both groups(P<0.05),with the observation group showing higher scores than the control group(P<0.05).The response rate in the observation group(52.78%)was higher than that in the control group(25.00%,P<0.05).No statistically significant difference was observed in the incidence of adverse reactions between the two groups(P>0.05).The overall survival rate in the observation group(72.22%)was higher than that in the control group(41.67%,χ2=6.269,P=0.012).Conclusion:Camrelizumab combined with TP chemotherapy can improve the response rate in patients with oesophageal cancer,improving T lymphocyte subset levels and quality of life,reducing the tumor marker levels,prolonging patient survival,without increasing the incidence of adverse reactions.关键词
食管癌/卡瑞利珠单抗/紫杉醇/顺铂/T淋巴细胞亚群/肿瘤标志物Key words
oesophageal cancer/camrelizumab/paclitaxel/cisplatin/T lymphocyte subsets/tumor marker分类
临床医学
